Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer (FastER)

University of Miami logo

University of Miami

Status

Begins enrollment in 1 month

Conditions

HER2-positive Breast Cancer
Advanced Breast Cancer

Treatments

Behavioral: Moderate-Intensity Exercise
Behavioral: General Health Education Sessions
Behavioral: Prolonged Overnight Fasting

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT06123988
20230599
R01CA281861 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to test if four different programs (prolonged overnighting fasting alone, exercise alone, a combination of prolonged overnight fasting and exercise, or general health education sessions alone) can reduce fatigue in women with advanced or metastatic breast cancer who are receiving a medication called a cyclin-dependent kinases-4 and 6 (CDK4/6) inhibitor.

Enrollment

260 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Women
  2. Able to provide written informed consent
  3. Able to read and understand English or Spanish
  4. Postmenopausal (including concurrent use of ovarian suppression)
  5. Diagnosis of ER+ and/or PR+, hormone estrogen receptor-2 (HER-2)- metastatic or locally advanced unresectable breast cancer
  6. Initiating first-line or second-line endocrine therapy in combination with a CDK4/6 inhibitor (e.g. palbociclib, ribociclib or abemaciclib). Participants can be enrolled up to 2 weeks after starting CDK4/6 inhibitor
  7. Having not consistently engaged in more than 90 minutes of moderate or 45 minutes of vigorous physical activity per week over the past 3 months
  8. Having not consistently engaged in resistance training 2 or more days per week over the past 3 months
  9. Having not consistently engaged in structured fasting (i.e., not regularly fasting for ≥12hr/night) for the past 3 months
  10. Approval from a medical oncology provider to participate.

Exclusion criteria

  1. Unable to provide consent
  2. Unable to read or understand English or Spanish
  3. Oxygen dependent
  4. Unstable cardiac disease
  5. Insulin-dependent diabetes
  6. Unable to walk 2 blocks without assistance (excluding canes)
  7. Unstable bone metastases
  8. More than 15 days from initiation of first- or second-line endocrine therapy in combination with a CDK4/6 inhibitor

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

Single Blind

260 participants in 4 patient groups

Prolonged Overnighting Fasting Alone (POF Alone) Group
Experimental group
Description:
Participants in this group will undergo a 12-week program of prolonged overnight fasting (POF), and weekly session with a trained health coach. Sessions may be delivered in-person, by telephone or by video call. Participants will also complete health-related quality of life questionnaires, and undergo blood sample collection at designated study timepoints. Total participant duration is about 12 months.
Treatment:
Behavioral: Prolonged Overnight Fasting
Exercise Alone (EXE Alone) Group
Active Comparator group
Description:
Participants in this group will undergo a 12-week exercise program during three weekly sessions supervised by a trained health coach. Sessions may be delivered in-person, or virtually via telehealth. Participants will also complete health-related quality of life questionnaires, and undergo blood sample collection at designated study timepoints. Total participant duration is about 12 months.
Treatment:
Behavioral: Moderate-Intensity Exercise
Prolonged Overnight Fasting and Exercise (POF+EXE) Group
Active Comparator group
Description:
Participants in this group will undergo a 12-week combined program of the prolonged overnight fasting and exercise interventions as described in the POF Alone and EXE Alone arm descriptions respectively. Participants will complete health-related quality of life questionnaires, and undergo blood sample collection at designated study timepoints. Total participation is about 12 months.
Treatment:
Behavioral: Prolonged Overnight Fasting
Behavioral: Moderate-Intensity Exercise
Attention Control (AC) Group
Other group
Description:
Participants in this group will receive other supportive care in the form of general health education sessions with a trained health coach. These bi-weekly sessions will be administered via telephone or video call in six (6) sessions over approximately 12 weeks. Participants will also complete health-related quality of life questionnaires at designated study timepoints. Total participation is about 12 months.
Treatment:
Behavioral: General Health Education Sessions

Trial contacts and locations

3

Loading...

Central trial contact

Grey Freylersythe, BS; Tracy E Crane, PhD, RDN

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems